Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BetaKine data

CTRX (Santa Clara, Calif.) released its final analysis of a 36-patient closed-label Phase II study of BetaKine to treat venous stasis ulcers. Patients in the treatment arm received 2.5 µg/cm 2 of BetaKine delivered in

Read the full 359 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE